China
Africa
Explore chapters and articles related to this topic
Reduction and Fixation of Sacroiliac joint Dislocation by the Combined Use of S1 Pedicle Screws and an Iliac Rod
Published in Kai-Uwe Lewandrowski, Donald L. Wise, Debra J. Trantolo, Michael J. Yaszemski, Augustus A. White, Advances in Spinal Fusion, 2003
Kai-Uwe Lewandrowski, Donald L. Wise, Debra J. Trantolo, Michael J. Yaszemski, Augustus A. White
Current medical management of ankylosing spondylitis focuses on symptom control as well as long-term disease modification. Four therapies form the mainstay of treatment: patient education, exercise, NSAIDs, and immune system-modifying agents [30]. Patients should be made aware of the possibility of disease progression and the risk of fractures related to fusion and secondary osteoporosis. Regular stretching and vigorous aerobic exercise appear to provide immediate gains in flexibility and may help decrease secondary osteoporosis of the spine by reducing immobility [31,32]. First-line drug therapy includes the use of NSAIDs for symptom control. Most NSAIDs have efficacy in pain management, with several having randomized trial proof of efficacy, including indomethacin, naproxen, and celecoxib [30]. NSAIDs reduce pain and morning stiffness but do not stop the course of the disease or the associated underlying inflammation of the spine [30,33]. In those patients with inflamed peripheral joints, the anti-inflammatory agent sulfasalazine and the immunosuppressant methotrexate and careful use of corticosteroids can be helpful, although none of these agents controls the spinal inflammation [30].
Catalytic ozonation oxidation of ketoprofen by peanut shell-based biochar: effects of the pyrolysis temperatures
Published in Environmental Technology, 2022
Haiquan Li, Sijia Liu, Siwei Qiu, Lei Sun, Xiangjuan Yuan, Dongsheng Xia
The presence of pharmaceuticals, especially the non-steroidal anti-inflammatory drugs (NSAIDs) in the aquatic environment is well recognized as a troublesome issue even at a trace concentration, due to their adverse effects on public health and environmental ecosystem [1]. Ketoprofen (KET) as a typical NSAIDs, has been widely used to treat ankylosing spondylitis, rheumatic arthritis, and osteoarthritis. KET was frequently detected in wastewater and surface water with concentrations ranging from ng L−1 up to μg L−1 [2]. Unfortunately, the high hydrophilicity and difficult biodegradation ability of KET have made its elimination relatively inefficient in wastewater treatment plants. In recent years, various efficient technologies such as advanced oxidation processes, photocatalysis, adsorption, and etc., have been adopted to eliminate the pharmaceutical pollutants in the aquatic environment [3,4].
Enhancement of anti-TNFα monoclonal antibody production in CHO cells through the use of UCOE and DHFR elements in vector construction and the optimization of cell culture media
Published in Preparative Biochemistry & Biotechnology, 2021
Chinh Chung Doan, Nguyen Quynh Chi Ho, Thi Thuy Nguyen, Thi Phuong Thao Nguyen, Dang Giap Do, Nghia Son Hoang, Thanh Long Le
Adalimumab is a typical tumor necrosis factor-α (TNFα) blocker that has been approved for the treatment of severe rheumatoid arthritis, psoriasis, ankylosing spondylitis, and moderate to severe Crohn’s disease.[1] Adalimumab is the first fully human recombinant monoclonal antibody (mAbTNFα) with a high binding affinity to TNFα.[2,3] Compared to other recombinant monoclonal TNFα antibodies, including etanercept or infliximab, adalimumab has a stronger binding affinity and neutralizes both soluble and transmembrane TNFα; it potentially kills TNFα-expressing cells through antibody-dependent cell-mediated cytotoxicity (ADCC) or/and complement-dependent cytotoxicity (CDC).[2,4–6] Furthermore, adalimumab causes less adverse immunogenic reactions than etanercept or infliximab in humans, making it suitable for the long-term treatment of chronic diseases.[2] Adalimumab has a longer circulation half-life (about 10–20 days) than that of etanercept (about 3–5 days) and infliximab (about 5–9 days). Therefore, patients can conveniently inject adalimumab every other week.[3,7] Among originator drugs, Humira, the brand name of the original adalimumab medicine, is frequently at the top of the selling record,[7] indicating the importance of this prescribed drug.
Video laryngoscopy-assisted tracheal intubation in airway management
Published in Expert Review of Medical Devices, 2018
Chia-Chih Liao, Fu-Chao Liu, Allen H. Li, Huang-Ping Yu
When tracheal intubation is required in patients with cervical spine injuries, insufficient immobilization of the neck can lead to devastating neurological consequences [78]. Maintaining the neck immobile by placing manual in-line stabilization is required in patients with an unstable neck and that has been shown to limit cervical spine movements during tracheal intubation [79]. Patients with severe ankylosing spondylitis are also difficult to intubate due to cervical spine rigidity [80]. Since cervical spine immobilization may lead to inadequate alignment of the oral, pharyngeal, and tracheal axes, it impairs visualization of the glottis when a direct laryngoscope is used [81]. Awake intubation using a flexible bronchoscope is often recommended for securing the airway in patients with cervical spine immobilization, but this technique is difficult to use in out-of-hospital emergency settings and a considerable amount of experience is required from the bronchoscopist [82].